<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Forte Biosciences Inc — News on 6ix</title>
    <link>https://6ix.com/company/forte-biosciences-inc</link>
    <description>Latest news and press releases for Forte Biosciences Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 08 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/forte-biosciences-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683567d478dffbe2df0f1165.webp</url>
      <title>Forte Biosciences Inc</title>
      <link>https://6ix.com/company/forte-biosciences-inc</link>
    </image>
    <item>
      <title>Forte Biosciences Announces Pricing of $150 Million Public Offering</title>
      <link>https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-announces-pricing-of-dollar150-million-public-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-announces-pricing-of-dollar150-million-public-offering</guid>
      <pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
      <description>DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related</description>
    </item>
    <item>
      <title>Forte Biosciences, Inc. Announces 2025 Results and Provides Update</title>
      <link>https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-announces-2025-results-and-provides-update-4</link>
      <guid isPermaLink="true">https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-announces-2025-results-and-provides-update-4</guid>
      <pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
      <description>DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and</description>
    </item>
    <item>
      <title>Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules</title>
      <link>https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-48</link>
      <guid isPermaLink="true">https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-48</guid>
      <pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
      <description>DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing</description>
    </item>
    <item>
      <title>Forte Biosciences, Inc. to Present at Upcoming Investor Meetings</title>
      <link>https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-present-upcoming-210100699</link>
      <guid isPermaLink="true">https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-present-upcoming-210100699</guid>
      <pubDate>Mon, 09 Feb 2026 21:01:00 GMT</pubDate>
      <description>DALLAS, February 09, 2026--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings.</description>
    </item>
    <item>
      <title>Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules</title>
      <link>https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-reports-inducement-210100111</link>
      <guid isPermaLink="true">https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-reports-inducement-210100111</guid>
      <pubDate>Mon, 22 Dec 2025 21:01:00 GMT</pubDate>
      <description>DALLAS, December 22, 2025--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules.</description>
    </item>
    <item>
      <title>Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update</title>
      <link>https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-announces-third-140000100</link>
      <guid isPermaLink="true">https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-announces-third-140000100</guid>
      <pubDate>Fri, 14 Nov 2025 14:00:00 GMT</pubDate>
      <description>DALLAS, November 14, 2025--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its third quarter 2025 financial results and provided a business update.</description>
    </item>
    <item>
      <title>Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules</title>
      <link>https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-reports-inducement-200100225</link>
      <guid isPermaLink="true">https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-reports-inducement-200100225</guid>
      <pubDate>Fri, 03 Oct 2025 20:01:00 GMT</pubDate>
      <description>DALLAS, October 03, 2025--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules.</description>
    </item>
    <item>
      <title>Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium</title>
      <link>https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-announces-presentation-130000176</link>
      <guid isPermaLink="true">https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-announces-presentation-130000176</guid>
      <pubDate>Mon, 15 Sep 2025 13:00:00 GMT</pubDate>
      <description>DALLAS, September 15, 2025--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced additional details from the oral presentation &quot;FB102 prevents histological damage and mitigates gluten challenge-induced symptoms in a celiac disease phase 1b study - Jason Tye-Din, Walter and Eliza Hall Institute; Royal Melbourne Hospital&quot; at the Tampere Celiac Disease Symposium 2025 (Tampere, Finland</description>
    </item>
    <item>
      <title>Forte Biosciences, Inc. Announces Results and Provides Update</title>
      <link>https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-announces-results-200100338</link>
      <guid isPermaLink="true">https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-announces-results-200100338</guid>
      <pubDate>Thu, 14 Aug 2025 20:01:00 GMT</pubDate>
      <description>DALLAS, August 14, 2025--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its second quarter 2025 financial results and provided a business update.</description>
    </item>
    <item>
      <title>Forte Biosciences Announces Pricing of $75 Million Public Offering</title>
      <link>https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-announces-pricing-75-042800683</link>
      <guid isPermaLink="true">https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-announces-pricing-75-042800683</guid>
      <pubDate>Wed, 25 Jun 2025 04:28:00 GMT</pubDate>
      <description>DALLAS, June 25, 2025--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,630,450 shares of its common stock at a price to the public of $12.00 per share and, in lieu of common stock to certain investors who so chose, pre-funded warrants to purchase up to 619,606 shares of common stock at a price to the public of $11.999 per pre-funded warrant, which repres</description>
    </item>
    <item>
      <title>Forte Biosciences Announces Proposed Public Offering</title>
      <link>https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-announces-proposed-public-200100631</link>
      <guid isPermaLink="true">https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-announces-proposed-public-200100631</guid>
      <pubDate>Tue, 24 Jun 2025 20:01:00 GMT</pubDate>
      <description>DALLAS, June 24, 2025--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. In addition, Forte expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of</description>
    </item>
    <item>
      <title>Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study</title>
      <link>https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-announces-positive-data-111800442</link>
      <guid isPermaLink="true">https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-announces-positive-data-111800442</guid>
      <pubDate>Mon, 23 Jun 2025 11:18:00 GMT</pubDate>
      <description>DALLAS, June 23, 2025--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive data from a Phase 1b trial in celiac disease for lead program FB102 (FB102-101).</description>
    </item>
    <item>
      <title>Forte Biosciences, Inc. Announces Results and Provides Clinical Update</title>
      <link>https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-announces-results-130000746</link>
      <guid isPermaLink="true">https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-announces-results-130000746</guid>
      <pubDate>Mon, 31 Mar 2025 13:00:00 GMT</pubDate>
      <description>DALLAS, March 31, 2025--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced full year 2024 results and provides a clinical update.</description>
    </item>
    <item>
      <title>Forte Biosciences to Host R&amp;D Day December 3, 2024</title>
      <link>https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-to-host-randd-day-december-3-2024</link>
      <guid isPermaLink="true">https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-to-host-randd-day-december-3-2024</guid>
      <pubDate>Mon, 25 Nov 2024 05:00:00 GMT</pubDate>
      <description>DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and</description>
    </item>
    <item>
      <title>Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications</title>
      <link>https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-announces-oversubscribed-dollar53-million-private-placement-from-leading-healthcare-institutional-investors-to-advance-fb102-across-autoimmune-indications</link>
      <guid isPermaLink="true">https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-announces-oversubscribed-dollar53-million-private-placement-from-leading-healthcare-institutional-investors-to-advance-fb102-across-autoimmune-indications</guid>
      <pubDate>Wed, 20 Nov 2024 05:00:00 GMT</pubDate>
      <description>DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and</description>
    </item>
    <item>
      <title>Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update</title>
      <link>https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-announces-third-quarter-2024-results-and-provides-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-announces-third-quarter-2024-results-and-provides-business-update</guid>
      <pubDate>Thu, 14 Nov 2024 05:00:00 GMT</pubDate>
      <description>DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and</description>
    </item>
    <item>
      <title>Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update</title>
      <link>https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-announces-second-quarter-2024-results-and-provides-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-announces-second-quarter-2024-results-and-provides-business-update</guid>
      <pubDate>Wed, 14 Aug 2024 04:00:00 GMT</pubDate>
      <description>DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and</description>
    </item>
    <item>
      <title>Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update</title>
      <link>https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-announces-first-quarter-2024-results-and-provides-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-announces-first-quarter-2024-results-and-provides-business-update</guid>
      <pubDate>Mon, 13 May 2024 04:00:00 GMT</pubDate>
      <description>DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and</description>
    </item>
    <item>
      <title>Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update</title>
      <link>https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-announces-2023-results-and-provides-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-announces-2023-results-and-provides-business-update</guid>
      <pubDate>Mon, 18 Mar 2024 04:00:00 GMT</pubDate>
      <description>DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and</description>
    </item>
    <item>
      <title>Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update</title>
      <link>https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-announces-third-quarter-2023-results-and-provides-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/forte-biosciences-inc/news/forte-biosciences-inc-announces-third-quarter-2023-results-and-provides-business-update</guid>
      <pubDate>Mon, 13 Nov 2023 05:00:00 GMT</pubDate>
      <description>DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune and</description>
    </item>
  </channel>
</rss>